Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's DiseaseBusiness Wire • 12/03/25
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rulesReuters • 12/01/25
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation PortfolioBusiness Wire • 12/01/25
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)Zacks Investment Research • 11/27/25
Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare ConferenceBusiness Wire • 11/26/25
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy BreyanziZacks Investment Research • 11/25/25
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell LymphomaBusiness Wire • 11/24/25
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed StudyBenzinga • 11/24/25
Bristol Myers Pops On A 'Surprisingly Positive' Update From Key Rival BayerInvestors Business Daily • 11/24/25
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?Zacks Investment Research • 11/20/25
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend YieldSeeking Alpha • 11/20/25
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender OffersBusiness Wire • 11/18/25